No Data
No Data
JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target
Trending Industry Today: ARK Genomic Revolution ETF Leads Losses In ARK ETFs Stocks
Adaptive Biotechnologies Analyst Ratings
Twist Bioscience Analyst Ratings
Natera Analyst Ratings
Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites
103721817 : stock exchange
Boganji4 : hello
curiousq : Bought some TMF last month, started to gain